The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study
Open Access
- 5 October 2025
- journal article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 16
Abstract
Background: Cardiovascular disease (CVD) has emerged as the most significant complication and leading cause of death among metabolic-associated fatty liver disease (MAFLD). Objectives: This study aims to investigate the CVD risk among MAFLD subgroups. Design: Data of participants from June 2017 to January 2023 in the Physical Examination Center of the Third Hospital of Hebei Medical University were collected. MAFLD were divided into four subgroups: metabolic healthy lean/normal weight MAFLD (MHL), metabolic healthy overweight/obese MAFLD (MHO), metabolic dysfunctional lean/normal weight MAFLD (MDL), and metabolic dysfunctional overweight/obese MAFLD (MDO). Methods: The risk assessment for atherosclerotic CVD was performed based on the flowchart for primary prevention risk assessment in Chinese adults. Results: The proportions of MHL, MHO, MDL, and MDO were 0.77% ( n = 185), 10.05% ( n = 2406), 1.29% ( n = 310), and 16.86% ( n = 4038), respectively. After adjustment for gender, age, smoking history, drinking history, and significant liver fibrosis, the subgroup of MAFLD was still an independent risk factor for high adverse cardiovascular events (HACE). Compared with the MHL, the MDL had the highest risk, followed by MDO (all p < 0.05), and there was no significant difference between MHO and MHL. We performed regression analysis according to age (65 years) and gender (male or female), respectively, and the results were similar to those of the total population. Conclusion: MAFLD is associated with a higher risk of CVD, especially in MDO. Classification of MAFLD based on body mass index and metabolic status helps in risk stratification, which will mitigate or prevent the development of CVD.Keywords
Funding Information
- National Natural Science Foundation of China (Grant No. 81970504)
- National Natural Science Foundation of China (No. 81970545)
- National Natural Science Foundation of China (No. 82170609)
- National Natural Science Foundation of China (No. BK20231118)
This publication has 41 references indexed in Scilit:
- Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral ObesityClinical Gastroenterology and Hepatology, 2017
- Anatomic fat depots and cardiovascular risk: a focus on the leg fat using nationwide surveys (KNHANES 2008–2011)Cardiovascular Diabetology, 2017
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Comparison of FIB‐4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non‐alcoholic fatty liver disease: A meta‐analysis studyHepatology Research, 2016
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2015
- Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort studyGut, 2015
- Estimation of 10-Year Risk of Fatal and Nonfatal Ischemic Cardiovascular Diseases in Chinese AdultsCirculation, 2006
- Predictive Value for the Chinese Population of the Framingham CHD Risk Assessment Tool Compared With the Chinese Multi-provincial Cohort StudyJAMA, 2004
- Appropriate body-mass index for Asian populations and its implications for policy and intervention strategiesThe Lancet, 2004
- Prediction of Coronary Heart Disease Using Risk Factor CategoriesCirculation, 1998